These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 25666752)

  • 1. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
    Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L; Houghton PJ
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells.
    Rosario FJ; Kanai Y; Powell TL; Jansson T
    J Physiol; 2013 Feb; 591(3):609-25. PubMed ID: 23165769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.
    Toschi A; Lee E; Gadir N; Ohh M; Foster DA
    J Biol Chem; 2008 Dec; 283(50):34495-9. PubMed ID: 18945681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
    Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
    Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.